Hemochromatosis

Clin Liver Dis. 2000 Feb;4(1):211-28, viii. doi: 10.1016/s1089-3261(05)70104-5.

Abstract

The recent cloning of the hemochromatosis gene (HFE) and the demonstration that a single missense mutation is responsible for 90% or more of patients with the disease, have stimulated renewed interest in all aspects of this common disease. The molecular tests for identifying mutations in HFE provide improved means for diagnosis, family screening, and population screening. Moreover, the elucidation of the role of the HFE gene product will provide new insights into the regulation of normal iron absorption and iron metabolism. In addition, it is now apparent that iron, even in the modest tissue concentrations, can act as a co-factor in potentiating cell injury in other liver diseases.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Female
  • Hemochromatosis / diagnosis*
  • Hemochromatosis / epidemiology
  • Hemochromatosis / therapy*
  • Humans
  • Incidence
  • Male
  • Prognosis
  • Risk Factors
  • Survival Rate